surpass cvot tirzepatide results Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the Clinical Trial Program | Cardiovascular Diabetology New SURPASS-CVOT Ad Hoc Analysis:

It is one of the main reasons providers prescribe sublingual formulations for patients who could not tolerate injectable tirzepatide due to nausea

Some people even alternate between both, which can be particularly frustrating

It is used along with diet and exercise as part of a long-term weight management plan

Prioritizing lean protein and key nutrients including iron, zinc, vitamin D, and essential fatty acids keeps hair growth strong

[Accessed on February 12, 2026] Weight-loss injections explained - British Heart Foundation

Among these serious adverse effects, AP has raised additional concerns, as MASLD clearly increases the risk of incidence and severity